Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
Status:
Terminated
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild
Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon
or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21
months (in Part 2).